PRIVILEGED AND CONFIDENTIAL ATTORNEY-CLIENT PRIVILEGE / ATTORNEY WORK PRODUCT
CALDERWOOD & HARKNESS LLP
MEMORANDUM
FROM: Leonard Cross, Responsible Partner, Tax Department, Calderwood & Harkness LLP Sylvia Hartwell, Billing Partner, Tax Department, Calderwood & Harkness LLP
TO: Marcus Whitfield, Vice President, Global Tax, Penterra Pharmaceuticals Corp. Deborah Staines, General Counsel, Penterra Pharmaceuticals Corp.
DATE: December 1, 2023
RE: Strategy for IRS Appeals — Transfer Pricing Examination of Penterra Pharmaceuticals Corp. (TY 2017–2020); IRS Exam Team LB&I-NE-TP-2022-00641
MATTER NO.: 1018-00009
DISTRIBUTION: RESTRICTED — Addressees only
cc: Rajesh Iyer, Chief Financial Officer, Penterra Pharmaceuticals Corp.
Copies to C&H working team under work-product protection: Garrett Simmons, Senior Associate; Leila Nazari, Senior Associate
Right-click to update Table of Contents
I. EXECUTIVE SUMMARY
The purpose of this memorandum is to outline a comprehensive strategy for pursuing the resolution of Penterra Pharmaceuticals Corp.'s ("PPC" or the "Company") transfer pricing examination at IRS Appeals, following the issuance of a Notice of Proposed Adjustment ("NOPA") on October 12, 2023, and the corresponding 30-Day Letter issued on November 8, 2023. This memorandum assesses the strengths and weaknesses of both PPC's positions and those of the IRS examination team, sets forth recommended settlement targets and boundaries, and provides a detailed plan for the preparation and filing of PPC's formal Protest, the Appeals conference, and contingency planning in the event that Appeals does not produce an acceptable resolution.
PPC intends to file a formal Protest by December 22, 2023, which is the extended deadline agreed to by Supervisory Revenue Agent Gerald Meskill following our request for an extension of the standard thirty-day response period. This deadline is firm, and the Protest drafting timeline set forth in Section V below has been calibrated to meet it with adequate time for client review.
The IRS examination team's proposed adjustments, as set forth in the NOPA, represent a net proposed adjustment of $380.4 million across Tax Years 2017 through 2020. The adjustments break down as follows:
• Cost-sharing arrangement (CSA) cost-sharing ratio adjustments: $235.01 million
• Legacy IP royalty rate adjustments: $188.04 million
• Less correlative offset: ($42.65 million)
• Net proposed adjustment: $380.4 million
In addition to the income adjustments, the IRS has proposed an IRC § 6662(e) substantial valuation misstatement penalty of approximately $15.98 million, calculated as 20% of the underpayment of tax attributable to the net adjustment (i.e., $380.4 million × 21% × 20%).
If the IRS's proposed adjustments were sustained in full, PPC's total cash exposure — inclusive of tax, penalty, and estimated interest — would be approximately $95.86 million in tax and penalty alone, plus accrued interest, representing a material financial exposure to the Company.
It is Calderwood & Harkness's assessment that PPC holds strong positions on all issues raised by the IRS examination team. Our analysis, supported by the robust economic work of Whitmore Valuation Group LLC ("Whitmore") under the direction of Dr. Helena Vasquez, and by the extensive evidence of Penterra Biopharma Ireland Ltd.'s ("PBI") economic substance in Ireland, demonstrates that PPC's intercompany transfer pricing complied with the arm's-length standard under IRC § 482 and the applicable Treasury Regulations throughout the examination period.
We recommend that PPC pursue an Appeals resolution targeting a settlement in the range of 10–15% of the proposed adjustment, or $38.0 million to $57.1 million in total income adjustment, with a hard ceiling of 20% ($76.1 million). At the target settlement range, PPC's total cash cost (inclusive of tax and estimated interest, but excluding professional fees) would be approximately $10.3 million to $15.4 million. We further believe that full penalty abatement is achievable and should be pursued as a threshold condition of any settlement, based on PPC's contemporaneous transfer pricing documentation and a robust reasonable-cause defense under IRC § 6662(e)(3)(B).
PPC's key strategic advantages in pursuing an Appeals resolution include:
• Rigorous economic analyses prepared by Whitmore, including a comparable uncontrolled transaction ("CUT") analysis supporting the 4.5% legacy IP royalty rate, a comparable profits method ("CPM") and transactional net margin method ("TNMM") analysis testing PBI's operating margins, and a discounted cash flow ("DCF") analysis supporting the $312 million platform contribution transaction ("PCT") payment;
• Extensive evidence of PBI's economic substance in Ireland, including 185 employees by 2020, 42 board meetings in Dublin during the examination period, €47.2 million in cumulative regulatory expenditures, and independent commercial decision-making across 68 country markets;
• Contemporaneous transfer pricing documentation prepared by Crestfield & Associates LLP, which satisfies the documentation requirements for penalty protection under IRC § 6662(e)(3)(B); and
• Favorable case law supporting PPC's positions, including the principles established in Altera Corp. v. Commissioner and Harborview Corporation, Inc. v. Commissioner regarding cost-sharing methodology and the best method rule.
Our overall objective is to resolve this matter at the IRS Appeals level to avoid the substantial cost, duration, and uncertainty of Tax Court litigation. The Appeals process, which applies a hazards-of-litigation standard, provides an opportunity for both sides to achieve a resolution that reflects the genuine risks each would face at trial. We are confident that a well-prepared Appeals presentation will demonstrate to the Appeals Officer that PPC's positions are well-founded and that a settlement at the levels recommended herein is appropriate.
We request that Marcus Whitfield and Deborah Staines confirm PPC's settlement authority parameters and schedule a call to discuss this strategy no later than December 8, 2023, in advance of the initial Protest drafting deadline.
II. BACKGROUND AND PROCEDURAL HISTORY
A. The IP Structure and Intercompany Arrangements
To provide appropriate context for the analysis that follows, we summarize below the relevant elements of PPC's corporate structure and intercompany arrangements that are at the center of the IRS examination.
1. Formation of PBI and the Cost-Sharing Arrangement
Penterra Biopharma Ireland Ltd. ("PBI") was incorporated in Ireland on March 15, 2012, as a wholly owned subsidiary of Penterra Holdings Luxembourg S.à r.l. ("PHL"), which is itself a direct subsidiary of PPC. PHL is treated as a disregarded entity for U.S. federal income tax purposes; accordingly, PBI is treated as a directly owned controlled foreign corporation of PPC for purposes of IRC § 482 and Subpart F.
Effective July 1, 2012, PPC and PBI entered into a Qualified Cost Sharing Arrangement (the "CSA") pursuant to Treas. Reg. § 1.482-7. Under the CSA, PBI acquired the right to develop and exploit PPC's pharmaceutical intellectual property outside of the Americas (i.e., in all territories other than North America, Central America, and South America, collectively referred to as the "non-Americas" territories). In exchange for the right to participate in the CSA and to receive the benefit of pre-existing IP, PBI made a platform contribution transaction ("PCT") payment of $312 million as a lump sum on July 1, 2012. This PCT payment represented the arm's-length compensation for PBI's buy-in to PPC's pre-existing intangible property portfolio, which at the time consisted primarily of PPC's oncology compound pipeline and related regulatory assets.
Under the CSA, PBI makes ongoing cost-sharing payments to PPC representing PBI's share of intangible development costs ("Coss"), calculated based on PBI's reasonably anticipated benefits ("RAB") from the CSA activity relative to PPC's reasonably anticipated benefits, expressed as a percentage of total coss. The cost-sharing ratios during the examination years were as follows:
The gradual increase in PBI's cost-sharing percentage over the examination period reflects the organic growth in PBI's non-Americas territory sales relative to PPC's Americas territory sales, consistent with the CSA methodology for updating RAB projections.
2. Legacy IP License Agreement
Separate from the CSA, PBI licenses certain pre-existing pharmaceutical compounds that were developed prior to the CSA's effective date (referred to as "legacy IP" or "pre-2012 compounds") from PPC under a separate intercompany license agreement (the "Legacy IP License"). Under the Legacy IP License, PBI pays a royalty to PPC of 4.5% of net sales of legacy products in the non-Americas territories.
The legacy IP product portfolio represents a declining revenue base, as these older products face patent expirations and generic competition. Net sales of legacy products in the non-Americas territories during the examination period were as follows:
The declining trajectory of legacy product sales is consistent with the expected lifecycle of pharmaceutical products facing patent expirations and was fully anticipated in PPC's transfer pricing analysis at the time the Legacy IP License was established.
3. PBI Functions, Assets, and Risks
PBI maintains its principal office at approximately 18,000 square feet of office space at Sandyford Business Park, Dublin, Ireland. Since its incorporation in 2012, PBI has grown significantly in both headcount and functional capability. By the end of the examination period, PBI employed approximately 185 employees (up from 52 at inception in 2012), organized across the following functional areas:
• Regulatory affairs — responsible for managing product registrations and regulatory submissions with the European Medicines Agency ("EMA"), national health authorities, and other non-Americas regulatory bodies;
• Medical affairs — overseeing clinical development activities in non-Americas territories, medical information services, and key opinion leader engagement;
• Commercial strategy — developing and executing commercial plans for each of the 68 country markets within PBI's territory, including pricing and reimbursement strategy, market access, and competitive positioning;
• Supply chain management — coordinating manufacturing schedules, inventory management, and distribution logistics for PBI's territory in collaboration with Penterra Manufacturing Ireland Ltd. ("PMI"); and
• General and administrative functions — including finance, human resources, legal, and compliance functions supporting PBI's operations.
PBI is led by Aidan Naughton, Managing Director, who has served in that role since 2013 and reports to PBI's board of directors. Mr. Naughton exercises significant decision-making authority with respect to PBI's commercial operations, regulatory strategy, and market investments.
PBI maintains independent banking relationships with Glenmore Bank Ireland plc and holds its own treasury function. PBI's board of directors, which includes both PPC nominees and independent non-executive directors, held a total of 42 board meetings in Dublin during the examination period (2017–2020), with comprehensive minutes and documented decision-making authority across PBI's key operational areas.
During the examination period, PBI incurred cumulative regulatory expenditures of approximately €47.2 million, reflecting PBI's direct investment in developing and maintaining product registrations in its non-Americas territories. PBI also made independent pricing decisions across its 68 country markets, taking into account local competitive conditions, reimbursement frameworks, and regulatory requirements — decisions that were not dictated by PPC headquarters.
4. Penterra Manufacturing Ireland Ltd. (PMI)
Penterra Manufacturing Ireland Ltd. ("PMI") is PBI's contract manufacturer, operating under a contract manufacturing agreement at a remuneration of cost plus 8%. PMI operates a manufacturing facility in Ringaskiddy, County Cork, Ireland, and employs approximately 620 employees. PMI's operations are limited to manufacturing and does not perform any IP-related functions. PMI is not a party to the CSA and is not a subject of the IRS's transfer pricing adjustment.
5. Penterra Holdings Luxembourg S.à r.l. (PHL)
PHL is an intermediate holding entity organized in Luxembourg. As noted above, PHL is disregarded for U.S. federal income tax purposes and serves as a holding vehicle within the group structure. PHL does not perform any substantive operational functions and is not directly relevant to the transfer pricing issues under examination.
6. Key Products
The principal products driving revenue during the examination period include the following:
Veritaxol is PPC's flagship oncology product and represents the single largest revenue contributor in both the Americas and non-Americas territories. Imvara, an immunology product, has experienced strong growth since its initial launch in 2015. Cerulon, addressing a rare disease indication, commands premium pricing and strong margins despite a smaller patient population.
B. The IRS Examination
The IRS initiated its examination of PPC's transfer pricing for Tax Years 2017 through 2020 on May 16, 2022, with the issuance of Letter 2205-A (notification of examination). The examination was conducted by the Large Business & International ("LB&I") Division, Northeast Transfer Pricing Practice, under case identification number LB&I-NE-TP-2022-00641.
The IRS examination team consisted of the following personnel:
• Gerald Meskill — Supervisory Revenue Agent (Team Manager)
• Patricia Dunleavy — Lead Revenue Agent
• Dr. Alan Washburne — IRS Economist
• Franklin Rosario — IRS Chief Counsel Attorney-Advisor
• Donna Hirabayashi — Senior Counsel (supporting Mr. Rosario)
Over the course of the examination, the IRS issued a total of 47 Information Document Requests ("IDRs") between June 2022 and September 2023. Calderwood & Harkness responded to all 47 IDRs on behalf of PPC, coordinating with PPC's internal tax team, PBI's management, and Whitmore Valuation Group as necessary. The IDRs covered a comprehensive range of topics, including the CSA structure and methodology, PCT valuation analysis, royalty rate benchmarking, PBI's functional analysis, employee compensation data, board minutes, internal strategic planning documents, and financial statements for PBI, PMI, and PHL.
Calderwood & Harkness was formally engaged by PPC on June 2, 2022, shortly after receipt of the examination notification. Whitmore Valuation Group LLC was retained under a Kovel arrangement on June 20, 2022 (reference number 1018-00009-KV), ensuring that Whitmore's economic analyses and communications with Calderwood & Harkness are protected by the attorney-client privilege and work-product doctrine. A Form 2848 (Power of Attorney) was filed with the IRS on June 8, 2022, designating Calderwood & Harkness as PPC's authorized representative for the examination.
The examination was conducted in a generally professional manner, though the IRS team, and Dr. Washburne in particular, adopted an increasingly aggressive posture as the examination progressed, particularly with respect to the PCT valuation and the economic substance of PBI. Calderwood & Harkness maintained a cooperative stance throughout the examination, while firmly defending PPC's positions in all substantive discussions with the examination team.
C. The NOPA and 30-Day Letter
On October 12, 2023, the IRS issued a NOPA covering all four tax years under examination (TY 2017–2020). The NOPA sets forth four principal IRS positions:
1. PCT Undervaluation. The IRS asserts that PPC's PCT payment of $312 million substantially understated the arm's-length value of the pre-existing IP contributed to the CSA. The IRS's own valuation, based on Dr. Washburne's DCF analysis at a 7.2% weighted average cost of capital ("WACC"), places the arm's-length PCT payment at $852 million. The IRS uses this asserted undervaluation as the foundation for its adjustments to the ongoing CSA cost-sharing ratios and, indirectly, to the royalty rate, asserting that the undervaluation "taints" the entire CSA structure.
2. CSA Cost-Sharing Ratio Adjustment ($235.01 million). The IRS proposes increasing PBI's cost-sharing percentages by 8 to 12 percentage points across all four years. The year-by-year proposed adjustments are set forth in detail in Section III.A below. The IRS asserts that PPC's projections of reasonably anticipated benefits systematically understated the value attributable to U.S.-based R&D contributions, resulting in PBI paying too little for its share of intangible development costs.
3. Legacy IP Royalty Rate Adjustment ($188.04 million). The IRS proposes increasing the royalty rate under the Legacy IP License from 4.5% to 11.0% of non-Americas net sales. The IRS's proposed rate is based on a set of allegedly comparable uncontrolled transactions selected by Dr. Washburne, which Calderwood & Harkness and Whitmore believe suffer from material comparability defects.
4. Economic Substance Challenge. The IRS challenges PBI's role as a genuine IP owner and CSA participant, asserting that key DEMPE functions (Development, Enhancement, Maintenance, Protection, and Exploitation of intangible property) remained in the United States throughout the examination period. This argument, if sustained, could potentially support a fundamental recharacterization of the entire intercompany arrangement.
The IRS allowed a correlative offset of $42.65 million to avoid double-counting between the CSA cost-sharing adjustment and the royalty rate adjustment, bringing the net proposed adjustment to $380.4 million.
In addition, the IRS proposed an IRC § 6662(e) substantial valuation misstatement penalty of approximately $15.98 million, calculated as 20% of the underpayment of tax attributable to the net adjustment ($380.4 million × 21% × 20% ≈ $15.98 million).
The 30-Day Letter was issued on November 8, 2023, informing PPC of its right to file a formal Protest and request a hearing before the IRS Office of Appeals. The standard thirty-day response period would have expired on December 8, 2023; however, Calderwood & Harkness, through Leonard Cross, obtained an agreement from Supervisory Revenue Agent Meskill to extend the Protest filing deadline through December 22, 2023.
III. ASSESSMENT OF IRS POSITIONS AND HAZARDS OF LITIGATION
This section provides our detailed assessment of each IRS position, evaluating the strengths and weaknesses of both the IRS's arguments and PPC's defenses. This hazards-of-litigation analysis is critical to formulating PPC's settlement posture at Appeals and to advising PPC on the appropriate parameters for settlement authority.
A. CSA Cost-Sharing Ratio Adjustment ($235.01 Million)
1. IRS Position
The IRS's cost-sharing ratio adjustment represents the largest single component of the proposed assessment. The IRS proposes increasing PBI's cost-sharing percentage by 8 to 12 percentage points across all four examination years, as set forth in the following table:
The IRS's basis for the proposed increase rests on several interrelated assertions. First, the IRS contends that PPC's projections of reasonably anticipated benefits systematically understated the value of U.S.-sourced R&D contributions to the CSA activity. The IRS argues that the projection methodology employed by PPC and Whitmore placed disproportionate weight on PBI's anticipated revenue growth while insufficiently accounting for the continuing centrality of PPC's U.S.-based R&D engine in generating the innovations that drove that growth.
Second, the IRS ties this adjustment partly to its assertion that the PCT payment was understated ($312 million vs. the IRS's $852 million valuation). The IRS's position is that the PCT undervaluation "infected" the entire CSA structure by establishing an artificially low baseline for PBI's cost-sharing obligations, and that the ongoing cost-sharing ratios should be recalculated to reflect the "true" value of the pre-existing IP contributed to the CSA.
Third, the IRS points to the fact that PBI's actual non-Americas revenue share grew over the examination period (with PBI's cost-sharing ratio increasing from 38.2% in 2017 to 42.7% in 2020) as evidence that PPC's RAB projections, while directionally correct, were insufficient in magnitude — i.e., that the growth trajectory was steeper than projected, suggesting the projections were designed to minimize PBI's cost-sharing obligations.
2. PPC Defense Strengths
PPC has several strong arguments against the IRS's proposed cost-sharing ratio adjustment:
Contemporaneous RAB Projections Were Reasonable. PPC's cost-sharing ratios were based on contemporaneous projections of reasonably anticipated benefits prepared in accordance with Treas. Reg. § 1.482-7. These projections were prepared at the inception of the CSA in 2012, with periodic updates as required by the regulations, and were based on detailed market analyses, product-level revenue forecasts, and probability-weighted assessments of pipeline success. Importantly, the actual results over the examination period were broadly consistent with the projections — the non-Americas share did grow, but the magnitude of the growth was within the range contemplated by PPC's projections.
Regulatory Methodology Followed. Treas. Reg. § 1.482-7 expressly permits the use of reasonably anticipated benefits as the basis for determining cost-sharing ratios, and PPC followed the regulatory methodology in all material respects. The IRS's position effectively asks that cost-sharing ratios be determined based on a hindsight analysis of actual results, which is inconsistent with the regulatory framework and the well-established principle that transfer prices should be evaluated based on information available at the time of the transaction.
Whitmore's CPM/TNMM Analysis. Whitmore's CPM/TNMM analysis tested PBI's operating margins against a set of 22 comparable IP-holding and distribution companies operating in the pharmaceutical sector. PBI's operating margins fell within the interquartile range in all four examination years, providing strong evidence that PBI's cost-sharing payments and overall profitability were consistent with arm's-length results.
PCT DCF Analysis Supports PPC's Valuation. Whitmore's DCF analysis of the PCT payment, using a WACC of 9.8%, places the $312 million payment within an arm's-length range of $278 million to $361 million. PPC's actual PCT payment of $312 million falls squarely within this range. The IRS's alternative WACC of 7.2% is inappropriately low given pharmaceutical-industry-specific risk premiums, and this issue is addressed in detail in the rebuttal materials being prepared by Dr. Vasquez and Dr. Chakrabarti.
Favorable Case Law. PPC's positions are supported by the principles established in Altera Corp. v. Commissioner, 941 F.3d 1200 (9th Cir. 2019), and Harborview Corporation, Inc. v. Commissioner, T.C. Memo. 2016-112, aff'd in part, rev'd in part, 900 F.3d 610 (8th Cir. 2018), regarding CSA methodology and the appropriate application of the best method rule. These cases underscore the Tax Court's reluctance to substitute hindsight-based analyses for contemporaneous arm's-length pricing.
3. PPC Defense Weaknesses and Litigation Hazards
Notwithstanding the strength of PPC's position, we identify the following vulnerabilities:
Facial Appeal of Revenue-Split Argument. The IRS's argument that PPC's projected revenue splits were biased toward understating U.S.-source value has some facial appeal, particularly given that the non-Americas share of global revenue did in fact grow over the examination period. While the growth was within the range contemplated by PPC's projections, the IRS may present this trend as evidence that PPC's projections were systematically conservative in a manner that benefited PBI at PPC's expense.
Tax Court Discretion. The Tax Court has broad discretion in evaluating the reasonableness of "reasonably anticipated benefits" projections and could adopt a middle-ground position that accepts neither PPC's projections nor the IRS's alternative in full. In prior cases, the Tax Court has occasionally fashioned its own analysis, selecting results that fall between the parties' competing positions. This risk counsels in favor of settlement, as the range of possible outcomes at trial is wider than the binary win/loss framework suggests.
Internal Documents. There is a risk that the IRS could present persuasive contemporaneous internal PPC documents — such as strategic planning presentations, board materials, or emails — showing that PPC's internal revenue projections for the non-Americas territories were, at certain points, more aggressive than the projections used to determine cost-sharing ratios. While we believe that the projections used for cost-sharing purposes were properly prepared and documented, any material divergence between internal business projections and transfer pricing projections could be seized upon by the IRS as evidence of intentional understatement.
Estimated Litigation Hazard. Taking into account the factors described above, we estimate a 20–30% probability that the IRS would prevail on a partial CSA cost-sharing ratio adjustment if the case were litigated in Tax Court. This does not mean that the full $235.01 million adjustment would be sustained; rather, it reflects the risk that the Tax Court could impose some upward adjustment to the cost-sharing ratios, potentially in the range of 2–4 percentage points.
B. Royalty Rate Adjustment ($188.04 Million)
1. IRS Position
The IRS proposes increasing the legacy IP royalty rate from 4.5% to 11.0% of non-Americas net sales. The year-by-year proposed adjustments are as follows:
The IRS's proposed rate of 11.0% is based on a set of allegedly comparable uncontrolled license agreements selected by IRS Economist Dr. Alan Washburne. The IRS asserts that these CUT comparables demonstrate that a willing licensor and licensee would agree to a royalty rate substantially in excess of PPC's 4.5% rate for pharmaceutical IP of the type and value at issue.
2. PPC Defense Strengths
PPC's defense on the royalty rate issue is among its strongest positions:
Whitmore CUT Analysis. Whitmore's CUT analysis, prepared by Dr. Vasquez, identified 14 comparable uncontrolled pharmaceutical license agreements through a rigorous and well-documented selection process. The interquartile range of royalty rates in these agreements is 3.1% to 6.8%, with a median of 4.4%. PPC's royalty rate of 4.5% falls squarely within this arm's-length range and is virtually identical to the median. This is among the most powerful facts in PPC's favor on any issue in this case.
IRS's Rate Well Above Upper Quartile. The IRS's proposed rate of 11.0% lies well above the upper quartile (6.8%) of Whitmore's CUT analysis. Under the arm's-length standard, an intercompany price that falls within the interquartile range of comparable transactions is presumptively arm's-length under Treas. Reg. § 1.482-1(e)(2)(iii)(B). The IRS's proposed rate, by contrast, lies far outside this range and is therefore difficult to sustain under the regulatory framework.
Comparability Defects in IRS's CUT Comparables. Calderwood & Harkness and Whitmore have identified material comparability defects in several of the CUT agreements selected by the IRS. These defects include:
• Agreements involving IP at different stages of development (e.g., pre-Phase III compounds, which typically command higher royalty rates due to the greater risk borne by the licensee);
• Agreements in different therapeutic areas with different commercial profiles and risk characteristics;
• Agreements with different geographic scope (e.g., worldwide licenses rather than territory-specific licenses); and
• Agreements that bundled manufacturing rights or co-promotion rights with the IP license, making it difficult to isolate the royalty component attributable to the IP alone.
These comparability defects undermine the reliability of the IRS's selected comparables and weigh heavily in favor of Whitmore's analysis, which employed more rigorous selection criteria and appropriate comparability adjustments.
Best Method Rule. Under Treas. Reg. § 1.482-1(d) (the "best method rule") and Treas. Reg. § 1.482-4 (governing the transfer of intangible property), the CUT method is the most reliable method when sufficiently comparable uncontrolled transactions can be identified. Whitmore's CUT analysis satisfies this standard, while the IRS's alternative CUT analysis suffers from the comparability defects noted above, rendering it less reliable under the best method rule.
3. PPC Defense Weaknesses and Litigation Hazards
Despite the strength of PPC's CUT analysis, we identify the following risks:
Tax Court May Select Its Own Rate. As with the CSA issue, the Tax Court has the authority to select its own royalty rate, which could fall somewhere between PPC's 4.5% and the IRS's 11.0%. While we believe the court would be most likely to select a rate at or near PPC's position, there is some risk that the court could land on a rate above 4.5% if it finds any merit in the IRS's comparability arguments.
Declining Sales Argument. The IRS may argue that the declining trajectory of legacy product sales should lead to a higher royalty rate rather than a lower one, on the theory that the remaining sales represent the most commercially valuable portion of the legacy IP portfolio (i.e., the products with the strongest competitive positions and the longest remaining patent life). While this argument has limited economic support, it could resonate with a Tax Court judge who views the declining revenue base as evidence that the remaining IP is particularly valuable.
Estimated Litigation Hazard. We estimate a 15–25% probability that the IRS would prevail on a partial royalty rate adjustment if the case were litigated in Tax Court. As with the CSA issue, this does not imply that the full $188.04 million adjustment would be sustained; rather, it reflects the risk that the Tax Court could impose a modest upward adjustment to the royalty rate, potentially in the range of 0.5–1.5 percentage points above PPC's 4.5% rate.
C. Economic Substance Challenge
1. IRS Position
The IRS's fourth and final position asserts that PBI lacked sufficient economic substance to justify its role as the IP owner and CSA participant for the non-Americas territories. The IRS contends that key DEMPE functions — Development, Enhancement, Maintenance, Protection, and Exploitation of intangible property — remained in the United States throughout the examination period, and that PBI's activities were more akin to those of a commissionaire or limited-risk distributor than a genuine IP owner exercising control over the development and exploitation of the intangible property.
This argument, if sustained, could result in a fundamental recharacterization of the entire CSA and Legacy IP License structure, potentially attributing all or substantially all of PBI's non-Americas income to PPC in the United States. The economic substance challenge thus has the potential to produce consequences far in excess of the specific dollar adjustments identified in the NOPA.
2. PPC Defense Strengths
PPC's defense on the economic substance issue is its strongest position overall, and is supported by extensive documentary and testimonial evidence:
Substantial Employee Base. PBI employed 185 employees by 2020, up from 52 at its inception in 2012. These employees perform genuine, substantive functions across regulatory affairs, medical affairs, commercial strategy, supply chain management, and general administration. This is not a case of a "letterbox" subsidiary with nominal employees; PBI is a fully operational entity with a substantial and growing workforce.
Corporate Governance. PBI's board of directors held 42 board meetings in Dublin during the examination period (2017–2020), with comprehensive minutes demonstrating that PBI's board exercised genuine decision-making authority over PBI's commercial strategy, pricing decisions, regulatory submissions, capital expenditure approvals, and other key operational matters.
Regulatory Expenditures. PBI incurred cumulative regulatory expenditures of €47.2 million during the examination period, reflecting PBI's direct investment in obtaining and maintaining product registrations with the EMA, national health authorities, and regulatory bodies in its 68 country markets. These expenditures are directly attributable to PBI's DEMPE functions and evidence PBI's genuine engagement in the development and enhancement of the intangible property within its territory.
Independent Commercial Decision-Making. Under the direction of Managing Director Aidan Naughton, PBI made independent pricing decisions across 68 country markets, taking into account local competitive conditions, government reimbursement frameworks, and regulatory requirements. PBI maintained independent banking relationships with Glenmore Bank Ireland plc and operated its own treasury function. PBI's commercial strategies were developed in Dublin and implemented through PBI's own commercial teams.
Functional Analysis Interviews. Calderwood & Harkness's functional analysis includes 12 key PBI employee interviews conducted during the examination period, which collectively demonstrate that PBI's employees exercise genuine decision-making authority with respect to the functions assigned to PBI under the CSA and Legacy IP License. These interviews are documented in contemporaneous memoranda and can be presented to the Appeals Officer as evidence of PBI's substance.
Physical Presence. PBI maintains approximately 18,000 square feet of office space at Sandyford Business Park, Dublin, with a growing footprint that reflects the entity's expanding operations and workforce.
OECD Guidelines. PBI's characterization is supported by the OECD Transfer Pricing Guidelines (both the 2017 and 2022 editions), which provide that an entity performing significant DEMPE functions, bearing genuine economic risks, and employing substantial personnel should be entitled to the returns attributable to those functions and risks. PBI meets all of these criteria.
3. PPC Defense Weaknesses and Litigation Hazards
Notwithstanding the strength of PPC's position on economic substance, we note the following risk factors:
Headquarters Influence. The IRS may point to certain strategic decisions — particularly those involving global brand positioning, R&D program prioritization, and major capital investments — that were influenced or approved by PPC headquarters in the United States. While PBI maintained genuine operational independence, it is undeniable that PPC, as the ultimate parent company, exercised some degree of oversight and coordination across the global enterprise. The IRS may seek to characterize this oversight as evidence that PBI lacked true control over the DEMPE functions attributed to it.
Early-Period Substance. PBI's substance in its earliest years of operation (2012–2014) was thinner than during the examination period, as the entity was still building its team and operational capabilities. While these years are not under examination, the IRS could use the narrative of PBI's "ramp-up" period to suggest that PBI was, at least initially, a shell entity, and that its substance during the examination period was merely a retroactive effort to support the transfer pricing position. We believe this argument is weak, as it ignores the natural and well-documented trajectory of an entity building genuine operations over time, but it could color the perception of a Tax Court judge or Appeals Officer.
Estimated Litigation Hazard. We estimate a 10–15% probability that the IRS would prevail on the economic substance challenge if the case were litigated in Tax Court. This is the lowest litigation hazard of the three substantive issues. However, we note that the consequences of an adverse determination on this issue would be severe — potentially resulting in a complete recharacterization of PBI's income — which means that even a relatively low probability of an adverse outcome carries significant risk-adjusted exposure. If the economic substance challenge were sustained, the resulting adjustments could exceed the $380.4 million currently proposed, as the IRS could seek to attribute all of PBI's operating income to PPC.
D. Overall Hazards-of-Litigation Summary
Based on the analysis set forth above, our overall assessment of the litigation hazards facing PPC can be summarized as follows:
Our ranking of PPC's positions, from strongest to most vulnerable, is as follows:
1. Strongest Position — Economic Substance. PBI has robust economic substance, supported by a growing employee base, extensive board governance, significant regulatory expenditures, and independent commercial decision-making. The IRS's economic substance challenge faces significant obstacles.
2. Second Strongest Position — Royalty Rate. PPC's CUT analysis, identifying 14 comparable agreements with a median royalty rate of 4.4%, strongly supports the 4.5% royalty rate. The IRS's proposed 11.0% rate is well above the upper quartile of comparable transactions and relies on comparables with material defects.
3. Most Vulnerable Position — CSA Cost-Sharing Ratios. While PPC's cost-sharing ratios are defensible, there is a modest litigation hazard associated with the projected revenue splits and the Tax Court's broad discretion in evaluating reasonably anticipated benefits.
Penalty Position. PPC has a strong reasonable-cause defense under IRC § 6662(e)(3)(B). PPC maintained contemporaneous transfer pricing documentation prepared by Crestfield & Associates LLP (under the direction of Susan Lam) that satisfies the documentation requirements of the statute and regulations. PPC had a reasonable basis for its positions on all issues, and the transfer pricing methodologies employed were consistent with the applicable regulations and supported by independent economic analyses. We believe there is a high probability of full penalty abatement.
IV. APPEALS SETTLEMENT POSTURE AND RECOMMENDED POSITIONS
A. Settlement Framework
The IRS Office of Appeals operates under a hazards-of-litigation standard, meaning that the Appeals Officer assigned to PPC's case will independently evaluate the strengths and weaknesses of both the IRS examination team's positions and PPC's positions, and will seek to fashion a resolution that reflects the genuine hazards of litigation faced by each side. Unlike the examination team, the Appeals Officer is not an advocate for the government's position; rather, the Appeals Officer functions as a neutral evaluator charged with resolving the dispute fairly and efficiently.
We expect PPC's case to be assigned to an Appeals Officer in January 2024, following the filing of PPC's Protest. Given the size and complexity of the case, it is likely that the case will be assigned to an experienced Appeals Officer with transfer pricing expertise, potentially within a specialized transfer pricing unit. Upon assignment, Calderwood & Harkness will request an Appeals conference for late February 2024, with a target date of February 28, 2024, at the IRS Appeals Office in Manhattan. We will send a letter to the assigned Appeals Officer requesting the conference promptly upon notification of the assignment.
It is important to note that the Appeals Officer will have access to the full examination file, including all IDR responses, PPC's transfer pricing documentation, the IRS economist's report, and the NOPA workpapers. Accordingly, the Appeals Officer will come to the conference with a substantial foundation of knowledge about the case, and PPC's presentation should be designed to supplement and contextualize this information rather than to repeat it.
B. Recommended Opening Position
PPC should open the Appeals conference by fully defending all of its positions — that is, PPC's opening position should be that no adjustment is warranted on any issue. This opening posture is appropriate for several reasons:
• It signals that PPC has genuine confidence in the strength of its positions and is not approaching the Appeals process from a position of weakness;
• It preserves maximum negotiating room for the settlement discussions that will follow the initial conference;
• It is consistent with PPC's obligation to accurately represent its positions, as PPC genuinely believes that its transfer pricing complied with the arm's-length standard in all respects; and
• It forces the Appeals Officer to evaluate the merits of the IRS's positions rather than starting from a presumption that some adjustment is warranted.
At the same time, PPC should signal its willingness to engage constructively in resolution discussions. The Appeals process works best when both sides demonstrate good faith, and PPC should make clear that it views the Appeals conference as an opportunity for genuine dialogue rather than mere advocacy.
On each specific issue, PPC's opening position should be as follows:
CSA Cost-Sharing Ratios: PPC's cost-sharing ratios are fully supportable under Treas. Reg. § 1.482-7 and reflect the arm's-length standard. The IRS examination team has not applied the best method rule and has relied on an inappropriately low WACC in its PCT valuation, which taints its entire CSA analysis. No adjustment is warranted.
Royalty Rate: PPC's 4.5% royalty rate falls within the arm's-length range established by 14 CUT comparables (median 4.4%, interquartile range 3.1%–6.8%). The IRS's proposed rate of 11.0% is well above the upper quartile and is based on comparables with material defects. No adjustment is warranted.
Economic Substance: PBI is a genuine, fully operational entity with substantial employees, independent governance, significant regulatory expenditures, and independent commercial decision-making across 68 country markets. The IRS's DEMPE-based challenge lacks factual support and should be rejected in its entirety.
Penalty: PPC maintained contemporaneous transfer pricing documentation that satisfies the requirements of IRC § 6662(e)(3)(B). PPC had a reasonable basis for all of its positions, which were supported by independent economic analyses prepared by qualified professionals. The penalty should be fully abated, and PPC should insist on full penalty abatement as a threshold condition of any settlement.
C. Target Settlement Range
Based on our hazards-of-litigation analysis, we recommend that PPC target a settlement in the range of 10–15% of the $380.4 million proposed adjustment, or a total adjustment of $38.0 million to $57.1 million across TY 2017–2020.
At the target settlement range, the financial impact to PPC would be approximately as follows:
*The blended rate reflects the 35% pre-TCJA rate applicable to TY 2017 and the 21% post-TCJA rate applicable to TY 2018–2020. The precise tax impact will depend on the year-by-year allocation of the settlement adjustment.
This target settlement range reflects PPC's probability-weighted exposure at the lower end of the range and represents an appropriate outcome given the strength of PPC's positions. Achieving a settlement in this range would represent an 84–90% reduction from the IRS's proposed adjustment and would save PPC tens of millions of dollars in tax, penalty, interest, and litigation costs relative to the worst-case scenario.
D. Hard Settlement Ceiling
We recommend establishing a maximum acceptable settlement at 20% of the $380.4 million proposed adjustment, or $76.1 million in total income adjustment. This ceiling translates to a maximum tax liability (at the blended rate) of approximately $16.0 million, plus estimated interest of approximately $4.6 million, for a maximum total cash cost of approximately $20.6 million (excluding professional fees).
If the Appeals Officer proposes a settlement above this 20% threshold, we recommend that PPC decline the settlement and proceed to Tax Court litigation. The rationale for this ceiling is as follows:
• At settlement levels above 20% of the proposed adjustment, the cost of settlement approaches PPC's probability-weighted litigation exposure, diminishing the economic rationale for settlement;
• PPC's positions are strong enough to warrant a judicial determination if the Appeals process does not produce a reasonable outcome;
• A settlement at or above 20% could set an adverse precedent for future examination cycles, potentially emboldening the IRS to adopt similarly aggressive positions in subsequent examinations of PPC's transfer pricing; and
• The strength of PPC's CUT analysis and economic substance evidence provides significant confidence that PPC would prevail at trial on the royalty rate and economic substance issues, respectively, which together represent approximately $188 million of the proposed adjustment.
We emphasize that proceeding to Tax Court is a contingency, not a preference. As discussed in Section VII below, Tax Court litigation is costly, time-consuming, and carries significant uncertainty. The Appeals process remains PPC's best opportunity for an efficient and favorable resolution.
E. Year-by-Year Allocation Considerations
If a settlement is reached, the total adjustment must be allocated across the four examination years. We recommend a proportional allocation based on each year's share of the total proposed adjustment, with the following considerations:
TY 2017 — Pre-TCJA Rate. The pre-TCJA corporate tax rate of 35% applies to TY 2017, compared to the 21% post-TCJA rate for TY 2018–2020. As a result, each dollar of income adjustment allocated to TY 2017 has a higher marginal tax impact than each dollar allocated to TY 2018–2020. In settlement negotiations, PPC should seek to minimize the share of the adjustment allocated to TY 2017 to the extent consistent with the overall settlement framework.
TY 2017 — Statute of Limitations. TY 2017 is the year closest to the expiration of the statute of limitations. PPC has executed Forms 872 (Consent to Extend the Time to Assess Tax) extending the assessment period for TY 2017 through December 31, 2024. If the Appeals process extends beyond this date, additional extensions may be required. PPC should avoid extending the TY 2017 statute of limitations beyond what is necessary to complete the Appeals process and any resulting Closing Agreement.
TY 2018–2020. The 21% post-TCJA rate applies to these years, and the statutes of limitations are less pressing. Proportional allocation based on each year's share of the total proposed adjustment is appropriate for these years.
F. Ancillary Settlement Considerations
In addition to the core settlement parameters discussed above, several ancillary issues must be addressed in connection with any settlement:
1. Correlative Adjustment
Any settlement must preserve the $42.65 million correlative offset allowed by the examination team to avoid double-counting between the CSA cost-sharing adjustment and the royalty rate adjustment. If the settlement reduces one or both of these adjustments, the correlative offset should be recalculated proportionally to ensure that PPC is not subject to double taxation.
2. GILTI and BEAT Interaction
A settlement adjustment will affect PBI's earnings and profits, which may in turn impact PPC's Global Intangible Low-Taxed Income ("GILTI") and Base Erosion and Anti-Abuse Tax ("BEAT") computations for TY 2018–2020 (the years to which GILTI and BEAT apply). Senior Associate Leila Nazari prepared a preliminary analysis of these interactions in October 2022, but this analysis should be updated once final settlement numbers are known. Depending on the magnitude and year-by-year allocation of the settlement adjustment, there could be additional tax consequences (or, potentially, partial offsets) arising from the GILTI and BEAT computations.
3. Competent Authority / Mutual Agreement Procedure (MAP)
If the settlement results in material double taxation — i.e., if the income adjustment to PPC is not accompanied by a corresponding reduction in PBI's Irish tax liability — PPC should consider requesting competent authority relief under Article 25 of the U.S.-Ireland Income Tax Treaty. A competent authority request would ask the U.S. and Irish competent authorities to agree on an appropriate allocation of income that avoids double taxation.
We will coordinate with PPC's Irish tax advisors at Thornbury & Keogh (contact: Ciarán Thornbury) on the Irish Revenue's likely position regarding any correlative adjustment in Ireland. Irish Revenue has historically been cooperative in competent authority proceedings involving transfer pricing adjustments, but the process can be lengthy (12–24 months) and the outcome is not guaranteed.
4. FIN 48 / ASC 740-10 Impact
PPC currently maintains an uncertain tax position ("UTP") reserve of $62.4 million under ASC 740-10 (formerly FIN 48) related to the transfer pricing issues under examination. Any settlement will require an adjustment to this reserve. A settlement at PPC's target range (10–15% of the proposed adjustment, or $38.0M–$57.1M) would release a substantial portion of the UTP reserve, resulting in a favorable impact to PPC's effective tax rate and earnings per share in the period in which the settlement is finalized.
We will coordinate with Crestfield & Associates LLP (contact: Martin Ogilvy, audit engagement partner) on the financial statement implications of the settlement, including the timing and magnitude of any UTP reserve adjustment. Crestfield should be kept informed of settlement developments on a timely basis to facilitate appropriate financial reporting.
5. Hargrove National Bank Credit Facility
PPC maintains a $1.5 billion revolving credit facility with a banking syndicate led by Hargrove National Bank (relationship manager: Christine Bellucci). The credit facility contains material-tax-event covenants that require PPC to notify the lenders in the event of a tax assessment or settlement exceeding certain thresholds. Senior Associate Nazari prepared a preliminary analysis of these covenants in November 2023, and this analysis should be finalized once the settlement parameters are known to determine whether notification to Hargrove is required.
We do not expect a settlement at PPC's target range to trigger the material-tax-event covenant, which we understand is set at a relatively high threshold. However, this should be confirmed through a careful review of the credit agreement language before any settlement is finalized.
6. SEC Disclosure
PPC is a publicly traded company (Nasdaq: PPCA) with SEC reporting obligations. The resolution of the IRS examination will need to be disclosed in PPC's periodic reports, including its 10-K annual report and 10-Q quarterly reports. The UTP reserve adjustment will flow through PPC's tax provision and affect its reported effective tax rate and earnings.
We note that Ridgeview Capital Management LP, a significant shareholder holding approximately 8.3% of PPC's outstanding shares (Managing Partner: Douglas Everett), closely monitors PPC's FIN 48 disclosures and has previously engaged with PPC's investor relations team regarding the Company's tax positions. We will coordinate with Deborah Staines on the appropriate disclosure language for the 10-K and 10-Q filings to ensure that the examination resolution is presented accurately and in a manner that does not create undue market concern.
7. State Tax Consequences